S
Sophine B. Krintel
Researcher at Copenhagen University Hospital
Publications - 20
Citations - 521
Sophine B. Krintel is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Adalimumab & Rheumatoid arthritis. The author has an hindex of 10, co-authored 19 publications receiving 460 citations. Previous affiliations of Sophine B. Krintel include Glostrup Hospital & Rigshospitalet.
Papers
More filters
Journal ArticleDOI
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
Kim Hørslev-Petersen,Merete Lund Hetland,Merete Lund Hetland,Peter Junker,Peter Junker,Jan Pødenphant,Jan Pødenphant,Torkell Ellingsen,Palle Ahlquist,Hanne Merete Lindegaard,Hanne Merete Lindegaard,Asta Linauskas,Annette Schlemmer,Annette Schlemmer,Mette Yde Dam,Ib Tønder Hansen,Hans Christian Horn,Christian Gytz Ammitzbøll,Anette Jørgensen,Sophine B. Krintel,Sophine B. Krintel,Johnny Lillelund Raun,Julia S. Johansen,Julia S. Johansen,Mikkel Østergaard,Mikkel Østergaard,Kristian Stengaard-Pedersen,Opera study-group +27 more
TL;DR: Adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment did not increase the proportion of patients who reached the DAS28CRP<3.2 treatment target, but improved DAS 28CRP, remission rates, function and quality of life in DMARD-naïve ERA.
Journal ArticleDOI
Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis.
Sophine B. Krintel,Giuseppe Palermo,Julia S. Johansen,Soren Germer,Laurent Essioux,Ryma Benayed,Laura Badi,Mikkel Østergaard,Merete Lund Hetland +8 more
TL;DR: No SNPs associated with treatment response to TNF&agr; inhibitors are found in a genome-wide association study of 196 genetically homogenous Danish patients with RA and in a meta-analysis of available studies.
Journal ArticleDOI
The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure
Sophine B. Krintel,Veit Peter Grunert,Merete Lund Hetland,Julia S. Johansen,Matthias Rothfuss,Giuseppe Palermo,Laurent Essioux,Ursula Klause +7 more
TL;DR: Early anti-infliximab antibody formation increased the risk of adverse drug reactions, including infusion reactions, and decreased the likelihood of minimal disease activity and remission in patients with RA treated in routine care.
Journal ArticleDOI
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial
Mette Bjørndal Axelsen,Iris Eshed,Kim Hørslev-Petersen,Kristian Stengaard-Pedersen,Merete Lund Hetland,J. Møller,Peter Junker,Jan Pødenphant,Annette Schlemmer,Torkell Ellingsen,Palle Ahlquist,Hanne Merete Lindegaard,Asta Linauskas,Mette Yde Dam,Ib Tønder Hansen,Hans Christian Horn,Christian Gytz Ammitzbøll,Anette Jørgensen,Sophine B. Krintel,Johnny Lillelund Raun,Niels Steen Krogh,Julia S. Johansen,Mikkel Østergaard,Mikkel Østergaard +23 more
TL;DR: A treat-to-target strategy with methotrexate and intra-articular glucocorticosteroid in patients with ERA effectively decreased synovitis, osteitis and tenosynovitis and halted structural damage progression as judged by MRI.
Journal ArticleDOI
Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis
Sophine B. Krintel,Christian Dehlendorff,Merete Lund Hetland,Kim Hørslev-Petersen,Klaus Kaae Andersen,Peter Junker,Jan Pødenphant,Torkell Ellingsen,Palle Ahlquist,Hanne Merete Lindegaard,Asta Linauskas,Annette Schlemmer,Mette Yde Dam,I. Hansen,Hans Christian Horn,Anette Jørgensen,Johnny Lillelund Raun,Christian Gytz Ammitzbøll,Mikkel Østergaard,Mikkel Østergaard,Kristian Stengaard-Pedersen,J.S. Johansen +21 more
TL;DR: To identify microRNAs (miRNAs) predictive of response to adalimumab in 180 treatment-naïve RA patients enrolled in the OPtimized treatment algorithm for patients with early RA (OPERA) Study, an investigator-initiated, prospective, double-blind placebo-controlled study, it is necessary to assess the utility of these miRNAs as predictive biomarkers.